Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fibrinogen in Liver Transplant Subjects
NCT06764927Phase 4Withdrawn
- Start
- Jan 2026
- Primary completion
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes, Tissue Cells
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of INTERCEPT Fibrinogen Complex in hypofibrinogenemia and hemorrhage (2 arms). Primary endpoint: Amount of blood products at 24 hours. Planned start Jan 2026; status: withdrawn.
02
Drugs
INTERCEPT Fibrinogen Complex
03
Conditions
hypofibrinogenemiahemorrhage
Beyond the preview
Go deeper on NCT06764927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06764927.